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Abstract: 1 
Systemic lupus erythematosus (SLE) is a chronic, heterogeneous 2 
autoimmune disorder characterized by inflammation, loss of tolerance to self-3 
antigens, and dysregulated interferon responses. In this study, we performed a 4 
genome-wide association scan to identify loci associated in 1174 Korean SLE 5 
cases and 4248 population controls. Ten regions outside the HLA exceeded the 6 
genome-wide significance threshold of P<5x10-8. Of these, 9 regions previously 7 
established SLE risk loci were replicated: STAT1-STAT4, TNFSF4, TNFAIP3, 8 
IKZF1, HIP1, IRF5, BLK, WDFY4, and ETS1. SNP-SLE association was also 9 
identified peaking at rs11235667 located between FCHSD2 and P2RY2 (P = 10 
1.0x10-8, odds ratio (OR) = 0.59, 95% confidence interval (CI)=0.50-0.71) on a 11 
haplotype spanning 33kb upstream to ATG16L2. Replication was tested for 12 
rs11235667 in an independent set of 1,412 SLE cases and 1,163 population 13 
controls of Korean and Chinese ancestries resulting in Pmeta-rep=0.001 and Pmeta-14 
overall=6.67x10-11 (OR=0.63, 95% CI=0.55-0.72). Within the HLA region, 15 
association peaked within the Class II at rs116727542 with multiple independent 16 
effects. Classical HLA allele imputation identified HLA-DRB1*1501 and HLA-17 
DQB1*0602 as most strongly associated with SLE. Of the established SLE risk 18 
loci, independent second effects not previously reported were observed in 19 
TNFAIP3 and TNFSF4, and differences in the association for a putative causal 20 
variant were identified in the WDFY4 region. Further studies are need to 21 
determine if any other suggestive loci are true SLE risk effects and to identify the 22 
causal variant(s) in the region of ATG16L2, FCHSD2, and P2RY2.  23 
 4 
Introduction: 1 
Systemic lupus erythematosus (SLE; [MIM152700]) is a chronic, 2 
heterogeneous autoimmune disease characterized by the loss of tolerance to 3 
self-antigens, dysregulated type I interferon (IFN) responses, and inflammation, 4 
often resulting in systemic end-organ damage1. Immune dysfunction of SLE 5 
involves both B and T lymphocytes of the adaptive immune system, together with 6 
elements of the innate immune system, including dendritic cells and the 7 
complement system1. The clinical manifestations of SLE can be quite variable 8 
and can involve virtually any organ system.  Although the precise etiology of SLE 9 
is largely unknown, the pathogenic mechanism likely involves environmental 10 
triggers in a genetically susceptible host2.  Few effective treatment options exist, 11 
largely due to the lack of a complete understanding of the pathophysiological 12 
basis of the disease. 13 
Genetic predisposition leading to an increased risk of SLE is supported by 14 
high heritability (>66%)3, increased risk among siblings of affected patients 15 
(λs≈30)4, and an ~25% monozygotic twin concordance5; 6.  Today, associations of 16 
more than 50 loci with SLE susceptibility have been identified and confirmed7.  17 
Many of these genes fall into known pathways that are key to innate and 18 
adaptive immune responses, lymphocyte activation and/or function, and immune 19 
complex clearance7.  However, a significant proportion of heritable risk to SLE 20 
has as of yet to be explained8.  The identification of SLE-associated genes and 21 
their pathogenic mechanisms will greatly enhance our understanding of lupus 22 
pathophysiology and facilitate the development of effective diagnostic, 23 
 5 
prognostic, and therapeutic tools.  To date, large-scale genome-wide genetic 1 
studies of Asian SLE populations have focused on Han Chinese9-11 and 2 
Japanese12.  Moreover, several reports have shown that transracial mapping of 3 
SLE loci can aid in the dissection of risk effects7.  In this study, we performed a 4 
genome-wide association (GWA) scan to identify genes associated with SLE in 5 
an East Asian population from Korea. 6 
 7 
Methods: 8 
Subjects:   9 
A total of 1,174 patients with SLE were recruited from the Hanyang 10 
University Hospital for Rheumatic Diseases (HUHRD) and six other university 11 
hospitals in Korea13.  In addition, 552 ethnically matched healthy controls were 12 
recruited from HUHRD.  The 3,700 ethnically matched out-of-study population 13 
controls were recruited from the Korean National Institutes of Health13.  In 14 
addition, an independent cohort of 1,412 SLE cases and 1,163 population 15 
controls were used for the replication studies14; 15.  This sample set consisted of 16 
739 Korean SLE cases and 436 Korean controls as well as 673 Chinese SLE 17 
cases and 727 Chinese controls (Supplementary Table 1). 18 
Written, informed consent from each participant was obtained by each 19 
participant following protocols approved by the Institutional Review Boards of 20 
participating institutes.  All cases used in this study fulfilled at least 4 of the 11 21 
American College of Rheumatology criteria for SLE16, while healthy, population-22 
based controls were without family history of SLE or any other autoimmune 23 
 6 
disease.   1 
GWA scan Genotyping, Sample Quality Control, and Ascertainment of 2 
Populations Stratification:  3 
Samples were genotyped using the Illumina HumanOmni1-Quad or 4 
HumanOmniExpress arrays using Infinium chemistry at Oklahoma Medical 5 
Research Foundation (OMRF) following the manufacturer’s protocol (Illumina, 6 
Inc., San Diego, CA).  The out-of-study GWA controls were genotyped on the 7 
HumanOmni1-Quad arrays by the Korea National Institutes of Health.  Strict 8 
quality control standards were implemented for SNPs retained in the association 9 
analysis, including requirements for well-defined cluster scatter plots.  Samples 10 
were excluded if they had a SNP call rate <90%.  SNPs were considered high 11 
quality SNPs if they had call rates >95%, no evidence of differential missingness 12 
between cases and controls (P < 0.05) and no evidence of a departure from 13 
expected Hardy-Weinberg proportions (controls P < 0.01, cases P < 14 
0.000001).  Inference is primarily based on those SNPs with minor allele 15 
frequency (MAF) greater than 1%. 16 
Based on the SNPs that passed the above quality control thresholds, 17 
samples were removed if there were inconsistencies between recorded and 18 
genotype-inferred gender or excess heterozygosity on the autosomes.  19 
Duplicates and first- or second-degree relatives were removed based on identity-20 
by-descent statistics computed by the program KING17.  Principal components 21 
were computed with the samples, merged with HapMap phase 3 individuals 22 
(CEU, YRI, and CHB) as reference populations18 using EIGENSOFT19.  PCA was 23 
 7 
performed on a subset of autosomal SNPs that were selected by removing 1 
regions of known high linkage disequilibrium (LD), removing variants with MAF < 2 
0.05, and pruning markers to reduce extended pairwise LD.  Admixture estimates 3 
were computed using the program ADMIXTURE20.  The principal components 4 
(PCs) and admixture estimates were used to remove genetic outliers 5 
(Supplementary Figure 1). The dataset that passed laboratory and statistical 6 
quality control was composed of 1174 SLE cases (1096 females and 78 males) 7 
and 548 within-study controls (547 females and 1 male).  In addition, 3698 out-of-8 
study controls (2330 females and 1368 males) were merged into the within-study 9 
genotype data.  10 
 11 
Statistical Analysis:  12 
To test for an association between a SNP and SLE status, a logistic 13 
regression analysis was computed including PC 1 as a covariate since no 14 
additional PC significantly changed the inflation factor (λ).  Primary inference was 15 
based on the additive genetic model, unless there was significant lack-of-fit (P < 16 
0.05).  If there was evidence of a departure from an additive model, then 17 
inference was based on the most significant value from the dominant, additive or 18 
recessive genetic models.  The additive and recessive models were computed 19 
only if there were at least 10 and 30 individuals homozygous for the minor allele, 20 
respectively.  The analyses were completed using the program SNPGWA version 21 
4.0.  For the analysis of chromosome X SNPs, the samples were stratified by 22 
gender and then meta-analyzed across gender using the program METAL21.   23 
 8 
To determine the number of independent associations within each SLE-1 
risk locus exceeding the genome-wide significance threshold, a manual stepwise 2 
model was computed.  The stepwise modeling was implemented using the 3 
following procedure:  forward selection with backward elimination using the entry 4 
and exit criteria of P < 0.0001 (accounting for approximately 500 independent 5 
variants within a given genomic region).  Specifically, for each region of interest, 6 
the top SNP was included as a covariate and the association statistics were re-7 
calculated.  SNPs were allowed to enter and exit models in this stepwise fashion 8 
until no additional SNPs met a significance threshold of P < 0.0001. 9 
 10 
Replication Genotyping, Sample Quality Control, and Ascertainment of 11 
Populations Stratification:   12 
Genotypes were obtained using TaqMan assays (Life Technologies, 13 
Grand Island, NY) for four SNPs:  rs2267828, rs10901656, rs11235667, and 14 
rs1048257.  Analysis was conducted for these cohorts independently to allow for 15 
PC analysis using previously collected data.  Ancestry adjustments for the 16 
Koreans were described previously in Lessard et al., 201214.  For the Chinese 17 
subjects, the PCA was done with slight modification from what was reported in 18 
Kaiser et al. 201315.  In this study, 7,918 randomly selected autosomal 19 
ImmunoChip SNPs with MAF>1%, low pairwise LD (r2 < 0.1), and no evidence of 20 
association with SLE (P > 0.01) were used to perform PC analysis using 21 
EIGENSOFT.  PC analysis plots of the CHB and CHS subjects in the 1000 22 
Genomes Project along with our subjects were used to select and remove 23 
 9 
genetic outliers.  The first principal component (Chinese cohort) and PCs 1, 2, 1 
and 3 (OMRF and UCLA Korean datasets) were included as covariates in the 2 
logistic regression models based on the variance explained in each dataset.  3 
These dataset were than meta-analyzed using the program METAL21.  To test for 4 
heterogeneity among the individual association results in the meta-analysis, we 5 
utilized both the Cochran's Q test statistic22 and I2 index23. 6 
 7 
Imputation:   8 
To help localize the associations in the genome-wide significant regions, 9 
ungenotyped genetic markers were imputed based on the reference panel from 10 
the 1000 Genomes Project24.  Specifically, the program SHAPEIT was used to 11 
pre-phase the genotype data25.  After phasing the data, IMPUTE2 was used for 12 
the imputation with the 1000 Genomes Phase I integrated reference 13 
panel26.  The imputed data was filtered using standard post-imputation quality 14 
control based on IMPUTE2 information scores >0.5 and confidence scores >0.9 15 
for subsequent association tests. Post-association analysis required genotyped 16 
SNPs in LD with imputed variants to support the inferred alleles as true signals. 17 
The program SNPTESTv2 was used to test for association on the imputed 18 
data27. 19 
Imputation of the HLA classical alleles in the genes HLA A, B, C, DPB1, 20 
DQA1, DQB1 and DRB1 was done using the program HiBAG28 and the Asian 21 
reference panel.  In this sample, ~21% of the reference SNPs used by HiBAG 22 
were missing genotype data.  To address this issue, HLA imputation was 23 
 10 
repeated after filling-in the missing genotype data with the “best guess” imputed 1 
SNP data from the 1000 Genomes imputation described above.  By using the 2 
“best guess” genotype data that had a posterior probability >0.90, the percent of 3 
missing SNPs in the reference set was reduced to 0.36%. 4 
 5 
Results: 6 
We observed a modest inflation in the test statistic (λ=1.09) with only slight 7 
deviation from expected once the HLA and other known SLE loci were removed 8 
(Supplementary Figure 2).  A total of eleven regions surpassed the genome-wide 9 
significance threshold of P < 5x10-8 with STAT4 (MIM600558) yielding the most 10 
significant genotyped association with SLE at rs11889341 (P = 8.02x10-19; Figure 11 
1 and Table 1).  Of the non-HLA regions, 9 risk loci had been previously 12 
identified and confirmed as risk loci for SLE, and included STAT1 (MIM600555)-13 
STAT4, IKZF1 (MIM603023), TNFAIP3 (MIM191163), TNFSF4 (MIM603594), 14 
HIP1 (MIM601767), IRF5 (MIM607218), ETS1 (MIM164740), BLK (MIM191305), 15 
and WDFY4 (MIM613316). In addition, association not previously described for 16 
SLE risk was observed at 11q14 (Figure 1).  This SNP-SLE association was 17 
observed with a single variant located between FCHSD2 (MIM not available) and 18 
P2RY2 (MIM600041) (rs11235667; P=1.03x10-8; odds ratio (OR) = 0.59; 95% 19 
confidence interval (CI) = 0.50-0.71; Figure 2, Table 2, and Supplementary Table 20 
2).  Moreover, additional support was observed with genotyped variants in the 21 
region (Supplementary Table 2).  After imputation of the 11q14 region showing 22 
association with SLE, rs11235667 remained the most significant association 23 
 11 
(Figure 2 and Supplementary Table 2).  However, a haplotype was identified with 1 
8 variants exceeding the genome-wide significance threshold spanning from 2 
ATG16L2 (MIM not available) through FCHSD2 to the shared promoter region 3 
with P2RY2. Stepwise logistic regression analysis adjusting for rs11235667 4 
indicated the presence of only a single effect (Supplementary Figure 3).  5 
Replication analysis for the primary signal in the region of FCHSD2-6 
P2RY2 was done using an independent cohort from Korea and China 7 
(Supplementary Table 1).  The SNP rs11235667 between FCHSD2 and P2RY2 8 
continued to show significant SLE association and similar effect size (Pmeta-rep = 9 
0.001; OR = 0.71, 95% CI = 0.57-0.87).  The overall meta-analysis between 10 
GWA and replication studies yielded a Pmeta-overall = 6.67x10-11 (OR = 0.63, 95% 11 
CI = 0.55-0.72; Table 2). No evidence of heterogeneity was observed in the 12 
meta-analysis (Table 2).  13 
Bioinformatics analysis using Haploreg v229 revealed that the region 14 
around rs11235667 was hypersensitive to DNase 1 in B cells by the ENCODE 15 
project30.  This variant has been shown to be located within an enhancer element 16 
in multiple immunological cell types based on the Epigenetic Roadmap data 17 
(Supplementary Table 3)31.  Chromatin immunoprecipitation followed by 18 
sequencing (ChIP-seq) experiments carried out by the ENCODE project found 19 
POL2 and YY1 proteins cross-linked to this region.  Moreover, sequence 20 
prediction methods indicate that rs11235667 can alter the binding motif for the 21 
FOXa family of transcription factors using sequence prediction methods 22 
according to Haploreg v229.  These data suggest the likely functional mechanism 23 
 12 
involves regulation of expression of ATG16L2, FCHSD2 and/or P2RY2.  1 
However, current eQTL databases do not suggest that rs11235667 influences 2 
the expression of these loci.  This could be due to the lack of data in the correct 3 
cell and/or tissue type and/or that some databases do not interrogate this SNP in 4 
their studies.   5 
Of the other 8 variants on the haplotype that exceeded genome-wide 6 
significance, rs11235604 had several findings that also make it intriguing as a 7 
potential causal variant (Supplemental Table 3).  This variant is a missense allele 8 
(R220W) that resides in the coding region of ATG16L2.  Although this 9 
polymorphism does change the amino acid sequence of the ATG16L2 protein, it 10 
is predicted to be benign by PolyPhen-232.  Haploreg v229 does report that 11 
rs11235604 alters 8 predicted regulatory motifs and is thought to be an active 12 
enhancer in several immunologically relevant cell types (Supplementary Table 3).  13 
Further work is needed to conclusively determine which polymorphism(s) are 14 
responsible for this association signal such as the following: evaluate the 15 
potential for rs11235667 impacts the expression of ATG16L2, FCHSD2 and/or 16 
P2RY2, the impact of the missense mutation arising from rs11235604 on 17 
ATG16L2, and/or any other variant(s) within this haplotype.  18 
One of the most consistent associations with SLE has been with the 19 
human leukocyte antigen (HLA) region.  Although the HLA was not the most 20 
statistically significant genotyped region, the SNP rs116727542 (P = 6.15x10-24; 21 
Table 3), which is located in a broad peak of association that was observed from 22 
HLA-DR (MIM142860) through -DQ (MIM146880), showed the strongest SNP-23 
 13 
SLE association after imputation (Figure 3, Table 3, and Supplementary Table 4).  1 
The interval between HLA-DR and -DQ has previously been implicated 2 
Koreans33.  In an attempt to identify the number of independent effects in this 3 
complex region, we used the stepwise approach described above and found ten 4 
independent effects (see Supplementary Figure 4A for results of the stepwise 5 
regression analysis).  The first four variants identified in the stepwise regression 6 
analysis, rs116727542, rs9273371, rs114653103, and rs115253455, are all 7 
located in the HLA Class II region (Figure 3, Supplementary Figure 4A, and 8 
Supplementary Table 4). 9 
To better understand the relationship between the variants reported in this 10 
study and the classical HLA alleles, we imputed alleles at HLA A, B, C, DPB1, 11 
DQA1, DQB1 and DRB1.  The peak statistical significance was observed at P = 12 
5.55x10-16 for both HLA-DRB1*1501 (OR = 1.85; 95% CI = 1.59-2.14) and HLA-13 
DQB1*0602 (OR = 1.90; 95% CI = 1.62-2.21; Figure 3, Table 4, and 14 
Supplementary Table 5).  Stepwise logistic regression modeling of the HiBAG-15 
imputed HLA alleles identified ten independent effects (Table 4).  To better relate 16 
the classical alleles to the variants identified in this GWA scan, stepwise 17 
modeling was done with both SNPs and classical HLA alleles.  The peak effect 18 
after 1000 Genomes imputation of SNPs, rs116727542, was accounted for by 19 
HLA-DQB1*0602 and HLA-DRB1*0803 (see Supplementary Figure 4B for results 20 
of stepwise regression analysis). 21 
Several previously identified non-HLA SLE loci were also replicated in this 22 
study, specifically the following: STAT1-STAT4, TNFSF4, TNFAIP3, IKZF1, 23 
 14 
HIP1, IRF5, BLK, WDFY4, and ETS1 (Table 1, Figure 4, Supplementary Figures 1 
5 to 10, and Supplementary Tables 6 to 14).   Of these loci, the associations in 2 
the region of TNFAIP3, TNFSF4, and WDFY4 have notable differences from 3 
previous studies.   4 
In the region of TNFAIP3 after imputation, the primary independent effect 5 
in the stepwise model was observed at rs5029937 (located within the second 6 
Intron of TNFAIP3 (Table 1 and Figure 4A).  The second independent effect was 7 
identified at rs9373203 around 3’ of the TNFAIP3 coding region.  A previous SLE 8 
study in Han Chinese9 reported rs2230926, and another SLE transracial mapping 9 
study in Koreans (with partial overlap of subjects with the current study) and 10 
Europeans34 identified risk of SLE with rs7749323.  Both variants (rs2230926 and 11 
rs7749323) are highly correlated with rs5029937, with D’ = 1.0 and r2 > 0.98, 12 
indicating our result is consistent with these previous reports (Supplementary 13 
Figure 11).  In addition, the second effect here tagged by rs9373203 was not 14 
identified in either the Han et al 2009 or Adrianto et al. 2011 (Figure 4A).  15 
Musone et al. 200835 identified multiple effects with some spanning even further 16 
3’ of TNFAIP3 than rs9373203.  However, after their stepwise analysis, they 17 
identified rs6922466 as the tagging variant that accounted for this association; in 18 
the current study of Koreans; however, this variant is not associated with SLE.  19 
Moreover, the LD between these variants is very weak in Koreans (r2 = 0.00; D’ = 20 
0.43), giving additional evidence that rs9373203 may be a true independent 21 
effect warranting further study (Supplementary Figure 11). 22 
 In the region of TNFSF4 after imputation, two independent effects were 23 
 15 
observed in the stepwise model.  The first effect, peaking at rs76413021, is 1 
located in the first intron of the TNFSF4 coding region (Table 1 and Figure 4B), 2 
and it is in linkage disequilibrium with rs2205960 (D’=0.98, r2=0.94) and 3 
rs1234315 (D’ = 0.97, r2 = 0.48), variants from the Han Chinese GWA scan9 4 
(Supplementary Figure 12).  Moreover, this effect is consistent with the results 5 
reported in Europeans36.  The second independent effect, which is distinct from 6 
the previous studies, peaks at rs4916342 (Figure 4B).  Neither the Han et al. 7 
20099 nor Cunninghame Graham et al. 200836 manuscripts describe association 8 
signals as far 5’ of TNFSF4 as our observation here with the second independent 9 
effect tagged by rs4916342.  In a transracial mapping study of this region by 10 
Manku et al. 201337 that included subjects from East Asia, a second independent 11 
effect was identified that is tagged by rs1234314.  In our current study of Koreans, 12 
we found that rs1234314 was accounted for in the stepwise model by 13 
rs76413021, the first effect.  Although rs1234314 and rs4916342 are located in 14 
the same general genomic location, the LD structure further supports that they 15 
are not the same genetic effect; however, all the risk variants are located on a 16 
single risk haplotype (Supplementary Figure 12).  This suggests that risk alleles 17 
for both rs76413021 and rs4916342 are needed to confer susceptibility to 18 
disease. 19 
In the region of WDFY4, the current study did not replicate rs877819, 20 
which has been previously reported to result in a down regulation of WDFY4 by 21 
modifying a YY1 binding site (Table 1)38.  However, the results for WDFY4 in 22 
Koreans are consistent with two previous studies.  First, the most statistically 23 
 16 
significant association within this region was rs7097397, a coding variant 1 
resulting in the amino acid substitution R1816Q (P = 2.10x10-9), previously 2 
reported by Yang et al. 201011.  Second, we also demonstrate association for 3 
rs1913517, which was identified previously by Han et al. 20099 (P = 2.54x10-5; 4 
Table 1 and Figure 4C).  Our haplotype and stepwise regression analysis 5 
indicated that there were two independent effects in the region, with rs7097397 6 
accounting for the association observed at rs1913517, and rs10857631 tagging 7 
the second independent effect (Figure 4C and Supplementary Figures 13 and 8 
14). 9 
In total, 15 genotyped variants surpassed the suggestive threshold of P < 10 
2x10-6 and were considered for further replication (Supplementary Table 15).  11 
Replication was attempted for three additional variants located within GTF2IRD1, 12 
DOCK1, and AHNAK2, all having multiple genotyped variants showing 13 
suggestive significance and/or having been previously implicated in other related 14 
phenotypes (Table 2).  Only rs2267828 near GTF2IRD1 yielded a Pmeta-rep < 0.05, 15 
but this variant did not surpass genome-wide significance after meta-analysis 16 
with the GWA scan (Table 2).  The variant in the region of AHNAK2, rs1048257, 17 
was trending towards significance, while rs10901656 near DOCK1 showed 18 
association in one replication dataset with the opposite allele (Table 2).  Outside 19 
of the 9 regions previously reported SLE loci described above, we observed only 20 
seven additional loci with P < 5x10-5 but P > 5x10-8 on the list of ~50 that have 21 
been described previously (Supplemental Table 16).  This is likely due to the 22 
limited power of this study and/or a result of population-specific differences from 23 
 17 
where the discoveries were originally identified.  1 
 2 
Discussion: 3 
The association in this region peaks between three candidate genes, 4 
ATG16L2, FCHSD2, and P2RY2, all of which have the biological potential to 5 
impact SLE pathophysiology.  While this locus has not been reported in other 6 
systemic autoimmune diseases, variants in this region are associated with 7 
Crohn’s disease (MIM266600) in Korean subjects39.  Moreover, the peak variant 8 
identified in Crohn’s disease, rs11235667, was also the variant discovered here 9 
in this current study with SLE.  The missense variant, rs11235604, was also 10 
reported to be associated in Crohn’s disease39.    11 
ATG16L2 (autophagy related 16-like 2) is a homologue of the gene 12 
ATG16L1 (MIM610767) that has been implicated as a risk locus for Crohn’s 13 
disease in patients of European descent40.  Both loci are involved in autophagy; 14 
however, not much is known about the role ATG16L2 plays in the process. 15 
Interestingly, this pathway has been implicated in SLE previously.  The gene 16 
ATG5 (MIM604261) has been previously implicated to be a risk locus for lupus9; 17 
41.  Studies in the mouse have shown that Apg16l (the mouse equivalent of 18 
human ATG16L) interacts with Apg5 (the mouse equivalent of human ATG5) 19 
suggesting that it is possible that ATG16L2 and ATG5 may interact too in the 20 
human42.  More studies are needed to understand the function ATG16L2 and if it 21 
is involved in this association signal. 22 
FCHSD2 (FCH and double SH3 domains 2) has been described as 23 
 18 
regulator of F-actin assembly through interactions with WAS (also known as 1 
WASP) and WASL (also known as N-WASP)43.  FCHSD2 is primarily expressed 2 
in CD19+ B cells and dendritic cells.  Previous studies have shown that WAS 3 
plays an important role in the migration of T cells through reorganization of the 4 
actin cytoskeleton subsequent to interactions with dendritic or B cells44.  5 
P2RY2 (purinergic receptor P2Y, G-protein coupled, 2) is known to be 6 
involved in many cellular functions and to be expressed in monocytes and 7 
myeloid cells.  P2RY2 is a receptor for ATP and UTP that acts as a sensor for 8 
the release of nucleotides by apoptotic cells45.  Mice null for P2RY2 showed a 9 
decreased ability to recruit monocytes and macrophages upon activation of 10 
nucleotides from apoptotic cells45.  P2RY2 is also known to induce CCL2 11 
secretion in macrophages, and coding variants in the receptor have been shown 12 
to influence secretion of this proinflammatory chemokine46.  13 
Although the HLA region has been implicated in SLE susceptibility since 14 
the 1970s, the precise loci responsible for risk have not been fully characterized. 15 
A further cross comparison of populations will be beneficial to take advantage of 16 
differences in linkage disequilibrium likely will help further refine association 17 
signals seen in the GWA studies.  For the classical alleles, previous studies have 18 
identified associations with alleles in the HLA-DR locus in Europeans, Chinese, 19 
Japanese, and Koreans, but HLA-DQB1*0602 has been implicated in Koreans 20 
before this current study47-50.  Two prominent Classical HLA alleles identified in 21 
Europeans with SLE showed differences in association in Koreans.  While HLA-22 
DRB1*15:01 was among the most significantly associated with SLE, HLA-23 
 19 
DRB1*03:01 was found to be at very low frequency in this population and not 1 
associated with SLE (Supplementary Table 5).  It is likely that there are several 2 
amino acid changing variants accounted for by the classical alleles that 3 
contribute to risk; however, more work is needed to determine if any non-coding 4 
RNAs or transcriptional changes also occur on these haplotypes. 5 
This GWA scan replicated several loci that have been identified by prior 6 
studies, including STAT1-STAT4, TNFSF4, TNFAIP3, IKZF1, HIP1, IRF5, BLK, 7 
WDFY4, and ETS1.  It is important to note that a previous GWA scan of Korean 8 
women with SLE has also reported replicating STAT4 and BLK at a genome-9 
wide significant level33.  Although most of the signals in these loci are identical, 10 
we did describe a couple of notable differences with independent effects in 11 
TNFSF4 and TNFAIP3.  Moreover, we did not observe association with 12 
rs877819, which had been proposed as putative causal variant leading to 13 
expression differences38. 14 
In conclusion, we performed a GWA scan of Korean SLE cases and 15 
population controls in which we identified 11 regions that surpassed genome-16 
wide significance.  The ATG16L2 through FCHSD2 to the promoter region of the 17 
P2RY2 locus was identified and confirmed as an SLE-associated region.  As has 18 
been widely reported since the 1970s, the HLA region was observed as a major 19 
risk factor for SLE.  Here, we also show the relationship between the classical 20 
HLA alleles and the variants reported within this GWA study in Koreans.  The 21 
nine additional regions, STAT4, IKZF1, TNFAIP3, TNFSF4, HIP1, IRF5, ETS1, 22 
BLK, and WDFY4, had previously been implicated in SLE.  Additional replication 23 
 20 
is needed for the suggestive loci identified in this study to determine their 1 
relationship with SLE.  Although GWA approaches have been very successful in 2 
the identification of risk loci, continued efforts are need to narrow association 3 
signals to the causal variant(s) and to determine the functional causal 4 
mechanism(s) contributing to SLE pathogenesis.    5 
 21 
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Figure 1.  Summary of the genome-wide association results for 1174 SLE 2 
cases and 3698 controls of Korean ancestry.  The -log10(P-value) for each 3 
genotyped variant is plotted along the Y-axis with the chromosome and 4 
chromosomal position along the X-axis.  The red dash line indicates the genome-5 
wide significance threshold of P = 5x10-8.6 
 29 
 1 
Figure 2.  Zoomed plot of the region associated with SLE at 11q14.  The -2 
log10(P-value) is shown for each genotyped (shown as circles) and imputed 3 
(shown as triangles) variants are plotted with the peak association, rs11235667, 4 
plotted as a diamond.  The linkage disequilibrium with rs11235667 is given by 5 
according to the scale on the figure.  The genome-wide significance threshold is 6 
displayed as a dashed line at P = 5 x10-8.  Association exceeding this threshold 7 
was found extending from ATG16L2 through FCHSD2 to the shared promoter 8 
region with P2RY2.    9 
 30 
Figure 3.  Expanded view of the association between SLE and the HLA 1 
region.  The –log10(P-value) is shown for each observed (shown as circles) and 2 
imputed (shown as triangles) in the MHC region plotted in base pair position from 3 
26Mb to 34Mb on chromosome 6.  Linkage disequibrium with the first four 4 
variants included in the stepwise logistic regression analysis is shown with 5 
rs116727542 (blue diamond), rs114653103 (red diamond), rs9273371 (green 6 
diamond), and rs115253455 (gold diamond) all located within the HLA Class II 7 
region.  The insert on the left shows the –log10(P-value) of the imputed classical 8 
alleles plotted according to base pair from 31Mb to 33.5Mb. 9 
 31 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.  Expanded view of the associations with SLE with TNFAIP3, 
TNFSF4, and WDFY4.  The -log10(P-value) is shown for each genotyped (shown 
as circles) and imputed (shown as triangles) variants are plotted for the region on 
Chromosome 6 in the region of TNFAIP3 (A), Chromosome 1 for the TNFSF4 (B) 
effects, and Chromosome 10 for WDFY4 (C).  For each independent effect, peak 
associations are represented by a diamond (blue for the first effect and red for 
the second, if applicable), and the correlation of variants accounted for by each 
effect is given in their respective color according the legends present in each 
plot.  The genome-wide significance threshold is displayed as a dashed line on 
each plot at P = 5 x10-8.  
A. 
B. 
C. 
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Table 1: Univaritae analysis of previous SLE associations outside of HLA region 
Marker ChrA Position Upstream Gene Downstream Gene Within Gene MAFB PGWAS Model Obs/Imp
C OR (95% CID) Maj/MinE 
rs1234314 1 173177392 1kb from TNFSF4 269kb from PRDX6 - 0.37 9.25x10-11 Add Imp 1.37 (1.25-1.51) C/G 
rs2205960 1 173191475 15kb from TNFSF4 255kb from PRDX6 - 0.25 1.03x10-11 Add Imp 1.44 (1.30-1.60) G/T 
rs76413021 1 173206297 30kb from TNFSF4 240kb from PRDX6 - 0.23 3.26x10-13 Add Imp 1.52 (1.36-1.71) G/A 
rs844644 1 173209495 33kb from TNFSF4 237kb from PRDX6 - 0.4 4.47x10-11 Add Obs 1.37 (1.25-1.50) A/C 
rs10489265 1 173236065 60kb from TNFSF4 211kb from PRDX6 - 0.25 8.19x10-12 Add Obs 1.43 (1.29-1.58) A/C 
rs4916342 1 173347837 172kb from TNFSF4 99kb from PRDX6 - 0.3 8.22x10-9 Add Imp 0.75 (0.67-0.82) A/G 
rs16833239 2 191940260 - - STAT4 0.15 9.69x10-10 Add Imp 0.67 (0.59-0.76) G/A 
rs11889341 2 191943742 - - STAT4 0.32 8.02x10-19 Add Obs 1.53 (1.40-1.69) C/T 
rs12612769 2 191953998 - - STAT4 0.31 2.37x10-19 Add Imp 1.59 (1.43-1.75) A/C 
rs13192841 6 137967214 152kb from OLIG3 221kb from TNFAIP3 - 0.13 7.50x10-3 Dom Obs 1.23 (1.06-1.43) G/A 
rs5029937 6 138195151 - - TNFAIP3 0.07 3.98x10-14 Dom Imp 2.11 (1.74-2.55) G/T 
rs5029939 6 138195723 - - TNFAIP3 0.07 4.09x10-14 Dom Imp 2.10 (1.74-2.55) C/G 
rs2230926 6 138196066 - - TNFAIP3 0.07 2.34x10-14 Dom Obs 1.93 (1.63-2.28) T/G 
rs9373203 6 138289848 86kb from TNFAIP3 120kb from PERP - 0.37 4.89x10-6 Add Imp 1.25 (1.14-1.37) C/T 
rs6922466 6 138444930 16kb from PERP 38kb from KIAA1244 - 0.18 0.297 Dom Obs 1.08 (0.94-1.24) A/G 
rs11185602 7 50299077 100kb from C7orf72 45kb from IKZF1 - 0.33 1.53x10-16 Add Imp 0.66 (0.60-0.73) A/G 
rs17552904 7 50318308 120kb from C7orf72 26kb from IKZF1 - 0.33 3.51x10-16 Add Obs 0.65 (0.59-0.72) G/T 
rs6964720 7 75180344 - - HIP1 0.24 2.00x10-10 Add Obs 1.40 (1.26-1.56) A/G 
rs139110493 7 75209951 - - HIP1 0.06 1.21x10-12 Dom Imp 2.48 (1.93-3.19) G/C 
rs4728142 7 128573967 11kb from LOC392787 4kb from IRF5 - 0.14 1.38x10-11 Add Obs 1.53 (1.35-1.73) G/A 
rs113478424 7 128575797 13kb from LOC392787 2kb from IRF5 - 0.14 3.97x10-12 Add Imp 1.59 (1.39-1.81) 15-mer*/T 
rs922483 8 11351912 - - BLK 0.25 2.00x10-10 Add Obs 0.71 (0.64-0.79) T/C 
rs2736345 8 11352485 - - BLK 0.24 7.88x10-11 Add Imp 0.70 (0.63-0.78) G/A 
rs10857631 10 49955821 - - WDFY4 0.13 1.67x10-4 Add Imp 1.30 (1.13-1.48) A/G 
rs7097397 10 50025396 - - WDFY4 0.37 2.10x10-9 Add Obs 1.33 (1.21-1.46) A/G 
rs877819 10 50042951 - - WDFY4 0.16 0.0558 Add Imp 1.13 (1.00-1.28) G/A 
rs10776651 10 50084526 - - WDFY4 0.34 1.54x10-7 Add Imp 1.29 (1.18-1.43) C/T 
rs1913517 10 50119054 - - WDFY4 0.31 2.54x10-5 Add Obs 1.24 (1.12-1.37) G/A 
rs12576753 11 128304141 None within 500kb 25kb from ETS1 - 0.39 1.74x10-11 Add Obs 1.37 (1.25-1.56) C/A 
rs1128334 11 128328959 - - ETS1 0.38 7.17x10-12 Add Imp 1.39 (1.26-1.52) G/A 
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A Chr = Chromosome 
B  MAF = Minor allele frequency 
C  Obs/Imp = observed/imputed 
D  CI = Confidence interval 
E  Maj/Min = Major/Minor allele 
*15-mer= CTTAGCTATTGCTC 
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Table 2: Univariate analysis results for regions genotyped in the replication study.  
Marker 
Region 
Name 
Maj/MinA 
MAFB       
Case / CtrlC 
PGWAS Model OR (95% CI
D) 
P  
Meta RepE 
Q / I2  
Meta RepE 
OR (95% CID) 
Meta RepE 
P  
Meta 
OverallF 
Q / I2  
Meta 
OverallF 
OR (95%CID) 
Meta Overall 
rs2267828 GTF2IRD1 A/G 0.40 / 0.45 7.02x10-7 Add 0.79 (0.72-0.87) 0.02 0.56 / 0 0.87 (0.77-0.98) 6.46x10-8 0.41 / 0 0.81 (0.76-0.88) 
rs10901656 DOCK1 C/T 0.27 / 0.23 6.91x10-7 Dom 1.39 (1.22-1.58) 0.095 0.6 / 0 1.14 (0.98-1.31) 9.56x10-6 0.23 / 28.72 1.21 (1.12-1.32) 
rs11235667 
FCHSD2-
P2RY2 
A/G 0.07 / 0.11 1.03x10-8 Add 0.59 (0.50-0.71) 0.0014 0.29 / 18.43 0.71 (0.57-0.87) 6.67x10-11 0.14 / 44.37 0.63 (0.55-0.72) 
rs1048257 AHNAK2 T/C 0.34 / 0.39 1.67x10-6 Add 0.79 (0.72-0.87) 0.086 0.29 / 17.06 0.90 (0.80-1.01) 8.66x10-7 0.12 / 47.82 0.82 (0.76-0.89) 
 
A  Maj/Min = Major/Minor allele 
B  MAF = Minor allele frequency 
C  Case/Ctrl = Case/Control 
D  CI = Confidence interval 
E  Meta Rep =  Meta-analysis for the replication 
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A All variants within this table have been imputed. 
B  CI = Confidence interval 
C MAF = Minor allele frequency 
D  Maj/Min = Major allele/Minor allele 
Note:  Tables are in the order they were identified in the stepwise model.  The stepwise results presented in this table are for adjusting 
for all other variants in the table.  For complete results in the HLA region, please refer to Supplementary Table 4. 
  
 
 
 
Table 3: Univariate and stepwise results for top ten independent HLA associations  
MarkerA Position Upstream Gene Downstream Gene 
Within 
Gene 
MAFB P-value 
OR 
(95%CIC) 
Maj/MinD 
Stepwise  
P-value 
Stepwise OR 
(95%CIC) 
rs116727542 32421227 8.4kb from HLA-DRA 64kb from HLA-DRB5 - 0.1700 6.15x10-24 
0.53 
(0.47-0.60) 
G/A 1.96x10-18 
1.74  
(1.54-1.97) 
rs9273371 32626565 14kb from HLA-DQA1 
675bp from HLA-
DQB1 
- 0.1000 1.18x10-9 
1.61 
(1.38-1.87) 
C/T 8.43x10-5 
1.38  
(1.18-1.63) 
rs114653103 32668846 34kb from HLA-DQB1 40kb from HLA-DQA2 - 0.1200 7.31x10-15 
0.57 
(0.49-0.66) 
G/T 1.81x10-13 
0.50 
(0.41-0.60) 
rs115253455 33100021 43kb from HLA-DPB1 30kb from COL11A2 - 0.1300 4.68x10-7 
0.70 
(0.61-0.80) 
T/A 4.51x10-7 
0.66 
(0.56-0.77) 
chr6:31996524 31996524 - - C4B 0.1700 4.95x10-8 
0.71 
(0.63-0.80) 
C/A 4.87x10-10 
0.64 
(0.55-0.73) 
rs113833333 32594898 37kb from HLA-DRB1 10kb from HLA-DQA1 - 0.4100 2.30x10-5 
0.82 
(0.74-0.90) 
C/T 3.09x10-8 
0.74 
(0.67-0.82) 
rs116427960 31319226 79kb from HLA-C 2.4kb from HLA-B - 0.0081 8.96x10-7 
4.57 
(2.49-8.38) 
C/T 1.69x10-5 
3.17 
(1.87-5.35) 
rs114904515 29362756 20kb from OR12D3 1.7kb from OR12D2 - 0.1000 1.55x10-6 
0.69 
(0.60-0.80) 
C/T 5.70x10-6 
0.67 
(0.56-0.79) 
rs118044183 30954150 - - MUC21 0.1200 3.61x10-6 
1.50 
(1.27-1.79) 
C/T 1.39x10-4 
1.39 
(1.17-1.64) 
rs2736191 31560910 ~150bp from NCR3 22kb from AIF1 - 0.3800 7.53x10-7 
0.79 
(0.71-0.86) 
C/G 1.01x10-4 
0.81 
(0.73-0.90) 
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A  CI = Confidence interval 
B  The allele HLA-DRB1*15:01 had the same P-value as HLA-DQB1*06:02, but the later was selected by the stepwise 
modeling procedure.  For complete results, please refer to Supplementary Table 5. 
Table 4: Univariate and stepwise results of HIBAG-imputed HLA dosages  
 Dosage Frequency Best Guess count     
HLA Allele Cases Controls Cases Controls OR 
(95% CIA) 
P-value Stepwise 
P-value 
Stepwise 
OR  
(95%CIA) 
DQB1*06:02B 0.25 0.15 301 636 1.90 
(1.62 - 2.21) 
5.55x10-16 1.93x10-23 2.35 
(1.99 – 2.78) 
DRB1*08:03 0.20 0.13 251 613 1.59 
(1.34 - 1.88) 
7.37x10-8 7.63x10-16 2.14 
(1.78 - 2.58) 
DQB1*02:02 0.18 0.12 212 502 1.60 
(1.35 - 1.90) 
7.57x10-8 2.19x10-18 2.50 
(2.04 - 3.07) 
DQA1*03:02 0.19 0.16 286 847 1.41 
(1.15 - 1.75) 
1.27x10-3 4.92x10-9 1.98 
(1.58 - 2.50) 
B*08:01 0.02 0.004 20 14 5.43 
(2.66 - 11.08) 
3.42x10-6 5.15x10-6 5.71 
(2.70 -12.07) 
DQA1*04:01 0.04 0.03 54 133 1.73 
(1.17 - 2.57) 
5.94x10-3 3.11x10-5 2.36 
(1.58 - 3.54) 
C*07:02 0.22 0.17 261 711 1.37 
(1.17 - 1.59) 
5.45x10-5 2.06x10-3 1.30 
(1.10 - 1.54) 
DRB1*04:06 0.03 0.07 41 354 0.15 
(0.09 - 0.26) 
2.63x10-11 1.11x10-4 0.32 
(0.18 - 0.57) 
DPB1*05:01 0.79 0.72 930 3092 1.16 
(1.05 - 1.28) 
2.87x10-3 1.06x10-4 1.23 
(1.11 - 1.36) 
DRB1*16:02 0.03 0.02 38 87 1.78 
(1.16 - 2.72) 
7.73x10-3 1.53x10-3 2.05 
(1.32 - 3.20) 
DPB1*17:01 0.03 0.04 41 160 0.90 
(0.62 - 1.30) 
5.66x10-1 1.07x10-3 0.5 
(0.33 - 0.76) 
C*01:02 0.29 0.32 359 1429 0.88 
(0.77 - 1.01) 
6.51x10-2 5.82x10-3 0.82 
(0.71 - 0.94) 
DRB1*12:02 0.04 0.07 39 266 0.52 
(0.37 - 0.74) 
2.98x10-4 7.07x10-3 0.61 
(0.42 - 0.87) 
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Note:  Tables are in the order they were identified in the stepwise model.  The stepwise results presented in this table are 
for adjusting for all other variants in the table. 
 
 
